Request Sample Inquiry
Car T-cell Therapy Market

CAR T-Cell Therapy Market

CAR T-Cell Therapy Market - Global Industry Assessment & Forecast

Number Of Pages # Pages:

180

Base Year:

2022

Date

Nov - 2023

Format:

PDF XLS PPT

Report Code:

VMR-2336

Segments Covered
  • By Drug Type By Drug Type Axicabtagene Ciloleucel, Tisagenlecleucel, Brexucabtagene Autoleucel, Other Drug Types
  • By Indication By Indication Lymphoma, Acute Lymphocytic Leukemia, Other Indications
  • By End User By End User Hospitals, Cancer Treatment Centers
  • By Region By Region North America, Europe, Asia Pacific, Latin America, Middle East & Africa
Snapshot
Base YearBase Year: 2022
Forecast YearsForecast Years: 2023 - 2030
Historical YearsHistorical Years: 2017 - 2021
Revenue 2022Revenue 2022: USD 2 Billion
Revenue 2030Revenue 2030: USD 5.9 Billion
Revenue CAGRRevenue CAGR (2023 - 2030): 14.6%
Fastest Growing Region Fastest Growing Region (2023 - 2030) Asia Pacific
Largest Region Largest Region (2022): North America
Customization Offered
  • Cross-segment Market Size and Analysis for Mentioned Segments Cross-segment Market Size and Analysis for Mentioned Segments
  • Additional Company Profiles (Upto 5 With No Cost) Additional Company Profiles (Upto 5 With No Cost)
  • Additional Countries (Apart From Mentioned Countries) Additional Countries (Apart From Mentioned Countries)
  • Country/Region-specific Report Country/Region-specific Report
  • Go To Market Strategy Go To Market Strategy
  • Region Specific Market Dynamics Region Specific Market Dynamics
  • Region Level Market Share Region Level Market Share
  • Import Export Analysis Import Export Analysis
  • Production Analysis Production Analysis
  • Other Others Request Customization Speak To Analyst
  1. Executive Dashboard
    1. Strategic Imperatives
  2. Premium Insights
    1. Top 3 Trends to Watch
    2. Demand and Supply Trends
    3. Top 3 Strategies Followed by Major Players
    4. Top 3 Predictions by Vantage Market Research
    5. Top Investment Pockets
    6. Insights from Primary Respondents
  3. Global CAR T-Cell Therapy Market - Segment Analysis
    1. Overview
    2. Global CAR T-Cell Therapy Market, 2016 - 2028 (USD Million)
    3. Global CAR T-Cell Therapy Market - by Drug Type
      1. By Axicabtagene Ciloleucel
      2. By Tisagenlecleucel
      3. By Brexucabtagene Autoleucel
      4. By Other Drug Types
    4. Global CAR T-Cell Therapy Market - by Indication
      1. By Lymphoma
      2. By Acute Lymphocytic Leukemia
      3. By Other Indications
    5. Global CAR T-Cell Therapy Market - by End User
      1. By Hospitals
      2. By Cancer Treatment Centers
    6. Global CAR T-Cell Therapy Market - by region
      1. North America
      2. Europe
      3. Asia Pacific
      4. Latin America
      5. Middle East & Africa
    7. Market comparative analysis
  4. North America CAR T-Cell Therapy Market - Segment Analysis
    1. Overview
    2. North America CAR T-Cell Therapy Market, 2016 - 2028 (USD Million)
    3. North America CAR T-Cell Therapy Market, by Drug Type
      1. By Axicabtagene Ciloleucel
      2. By Tisagenlecleucel
      3. By Brexucabtagene Autoleucel
      4. By Other Drug Types
    4. North America CAR T-Cell Therapy Market, by Indication
      1. By Lymphoma
      2. By Acute Lymphocytic Leukemia
      3. By Other Indications
    5. North America CAR T-Cell Therapy Market, by End User
      1. By Hospitals
      2. By Cancer Treatment Centers
    6. North America CAR T-Cell Therapy Market, by Country
      1. U.S.
        1. U.S. CAR T-Cell Therapy Market, By Drug Type
          1. By Axicabtagene Ciloleucel
          2. By Tisagenlecleucel
          3. By Brexucabtagene Autoleucel
          4. By Other Drug Types
        2. U.S. CAR T-Cell Therapy Market, By Indication
          1. By Lymphoma
          2. By Acute Lymphocytic Leukemia
          3. By Other Indications
        3. U.S. CAR T-Cell Therapy Market, By End User
          1. By Hospitals
          2. By Cancer Treatment Centers
      2. Canada
        1. Canada CAR T-Cell Therapy Market, By Drug Type
          1. By Axicabtagene Ciloleucel
          2. By Tisagenlecleucel
          3. By Brexucabtagene Autoleucel
          4. By Other Drug Types
        2. Canada CAR T-Cell Therapy Market, By Indication
          1. By Lymphoma
          2. By Acute Lymphocytic Leukemia
          3. By Other Indications
        3. Canada CAR T-Cell Therapy Market, By End User
          1. By Hospitals
          2. By Cancer Treatment Centers
      3. Mexico
        1. Mexico CAR T-Cell Therapy Market, By Drug Type
          1. By Axicabtagene Ciloleucel
          2. By Tisagenlecleucel
          3. By Brexucabtagene Autoleucel
          4. By Other Drug Types
        2. Mexico CAR T-Cell Therapy Market, By Indication
          1. By Lymphoma
          2. By Acute Lymphocytic Leukemia
          3. By Other Indications
        3. Mexico CAR T-Cell Therapy Market, By End User
          1. By Hospitals
          2. By Cancer Treatment Centers
  5. Europe CAR T-Cell Therapy Market - Segment Analysis
    1. Overview
    2. Europe CAR T-Cell Therapy Market, 2016 - 2028 (USD Million)
    3. Europe CAR T-Cell Therapy Market, by Drug Type
      1. By Axicabtagene Ciloleucel
      2. By Tisagenlecleucel
      3. By Brexucabtagene Autoleucel
      4. By Other Drug Types
    4. Europe CAR T-Cell Therapy Market, by Indication
      1. By Lymphoma
      2. By Acute Lymphocytic Leukemia
      3. By Other Indications
    5. Europe CAR T-Cell Therapy Market, by End User
      1. By Hospitals
      2. By Cancer Treatment Centers
    6. Europe CAR T-Cell Therapy Market, by Country
      1. Germany
        1. Germany CAR T-Cell Therapy Market, By Drug Type
          1. By Axicabtagene Ciloleucel
          2. By Tisagenlecleucel
          3. By Brexucabtagene Autoleucel
          4. By Other Drug Types
        2. Germany CAR T-Cell Therapy Market, By Indication
          1. By Lymphoma
          2. By Acute Lymphocytic Leukemia
          3. By Other Indications
        3. Germany CAR T-Cell Therapy Market, By End User
          1. By Hospitals
          2. By Cancer Treatment Centers
      2. UK
        1. UK Market, By Drug Type
          1. By Axicabtagene Ciloleucel
          2. By Tisagenlecleucel
          3. By Brexucabtagene Autoleucel
          4. By Other Drug Types
        2. UK Market, By Indication
          1. By Lymphoma
          2. By Acute Lymphocytic Leukemia
          3. By Other Indications
        3. UK Market, By End User
          1. By Hospitals
          2. By Cancer Treatment Centers
      3. France
        1. France CAR T-Cell Therapy Market, By Drug Type
          1. By Axicabtagene Ciloleucel
          2. By Tisagenlecleucel
          3. By Brexucabtagene Autoleucel
          4. By Other Drug Types
        2. France CAR T-Cell Therapy Market, By Indication
          1. By Lymphoma
          2. By Acute Lymphocytic Leukemia
          3. By Other Indications
        3. France CAR T-Cell Therapy Market, By End User
          1. By Hospitals
          2. By Cancer Treatment Centers
      4. Spain
        1. Spain CAR T-Cell Therapy Market, By Drug Type
          1. By Axicabtagene Ciloleucel
          2. By Tisagenlecleucel
          3. By Brexucabtagene Autoleucel
          4. By Other Drug Types
        2. Spain CAR T-Cell Therapy Market, By Indication
          1. By Lymphoma
          2. By Acute Lymphocytic Leukemia
          3. By Other Indications
        3. Spain CAR T-Cell Therapy Market, By End User
          1. By Hospitals
          2. By Cancer Treatment Centers
      5. Italy
        1. Italy CAR T-Cell Therapy Market, By Drug Type
          1. By Axicabtagene Ciloleucel
          2. By Tisagenlecleucel
          3. By Brexucabtagene Autoleucel
          4. By Other Drug Types
        2. Italy CAR T-Cell Therapy Market, By Indication
          1. By Lymphoma
          2. By Acute Lymphocytic Leukemia
          3. By Other Indications
        3. Italy CAR T-Cell Therapy Market, By End User
          1. By Hospitals
          2. By Cancer Treatment Centers
      6. BENELUX
        1. BENELUX CAR T-Cell Therapy Market, By Drug Type
          1. By Axicabtagene Ciloleucel
          2. By Tisagenlecleucel
          3. By Brexucabtagene Autoleucel
          4. By Other Drug Types
        2. BENELUX CAR T-Cell Therapy Market, By Indication
          1. By Lymphoma
          2. By Acute Lymphocytic Leukemia
          3. By Other Indications
        3. BENELUX CAR T-Cell Therapy Market, By End User
          1. By Hospitals
          2. By Cancer Treatment Centers
      7. Rest of Europe
        1. Rest Of Europe CAR T-Cell Therapy Market, By Drug Type
          1. By Axicabtagene Ciloleucel
          2. By Tisagenlecleucel
          3. By Brexucabtagene Autoleucel
          4. By Other Drug Types
        2. Rest Of Europe CAR T-Cell Therapy Market, By Indication
          1. By Lymphoma
          2. By Acute Lymphocytic Leukemia
          3. By Other Indications
        3. Rest Of Europe CAR T-Cell Therapy Market, By End User
          1. By Hospitals
          2. By Cancer Treatment Centers
  6. Asia Pacific CAR T-Cell Therapy Market - Segment Analysis
    1. Overview
    2. Asia Pacific CAR T-Cell Therapy Market, 2016 - 2028 (USD Million)
    3. Asia Pacific CAR T-Cell Therapy Market, by Drug Type
      1. By Axicabtagene Ciloleucel
      2. By Tisagenlecleucel
      3. By Brexucabtagene Autoleucel
      4. By Other Drug Types
    4. Asia Pacific CAR T-Cell Therapy Market, by Indication
      1. By Lymphoma
      2. By Acute Lymphocytic Leukemia
      3. By Other Indications
    5. Asia Pacific CAR T-Cell Therapy Market, by End User
      1. By Hospitals
      2. By Cancer Treatment Centers
    6. Asia Pacific CAR T-Cell Therapy Market, by Country
      1. China
        1. China CAR T-Cell Therapy Market, By Drug Type
          1. By Axicabtagene Ciloleucel
          2. By Tisagenlecleucel
          3. By Brexucabtagene Autoleucel
          4. By Other Drug Types
        2. China CAR T-Cell Therapy Market, By Indication
          1. By Lymphoma
          2. By Acute Lymphocytic Leukemia
          3. By Other Indications
        3. China CAR T-Cell Therapy Market, By End User
          1. By Hospitals
          2. By Cancer Treatment Centers
      2. Japan
        1. Japan CAR T-Cell Therapy Market, By Drug Type
          1. By Axicabtagene Ciloleucel
          2. By Tisagenlecleucel
          3. By Brexucabtagene Autoleucel
          4. By Other Drug Types
        2. Japan CAR T-Cell Therapy Market, By Indication
          1. By Lymphoma
          2. By Acute Lymphocytic Leukemia
          3. By Other Indications
        3. Japan CAR T-Cell Therapy Market, By End User
          1. By Hospitals
          2. By Cancer Treatment Centers
      3. India
        1. India CAR T-Cell Therapy Market, By Drug Type
          1. By Axicabtagene Ciloleucel
          2. By Tisagenlecleucel
          3. By Brexucabtagene Autoleucel
          4. By Other Drug Types
        2. India CAR T-Cell Therapy Market, By Indication
          1. By Lymphoma
          2. By Acute Lymphocytic Leukemia
          3. By Other Indications
        3. India CAR T-Cell Therapy Market, By End User
          1. By Hospitals
          2. By Cancer Treatment Centers
      4. South Korea
        1. South Korea CAR T-Cell Therapy Market, By Drug Type
          1. By Axicabtagene Ciloleucel
          2. By Tisagenlecleucel
          3. By Brexucabtagene Autoleucel
          4. By Other Drug Types
        2. South Korea CAR T-Cell Therapy Market, By Indication
          1. By Lymphoma
          2. By Acute Lymphocytic Leukemia
          3. By Other Indications
        3. South Korea CAR T-Cell Therapy Market, By End User
          1. By Hospitals
          2. By Cancer Treatment Centers
      5. South East Asia
        1. South East Asia CAR T-Cell Therapy Market, By Drug Type
          1. By Axicabtagene Ciloleucel
          2. By Tisagenlecleucel
          3. By Brexucabtagene Autoleucel
          4. By Other Drug Types
        2. South East Asia CAR T-Cell Therapy Market, By Indication
          1. By Lymphoma
          2. By Acute Lymphocytic Leukemia
          3. By Other Indications
        3. South East Asia CAR T-Cell Therapy Market, By End User
          1. By Hospitals
          2. By Cancer Treatment Centers
      6. Rest of Asia Pacific
        1. Rest of Asia Pacific CAR T-Cell Therapy Market, By Drug Type
          1. By Axicabtagene Ciloleucel
          2. By Tisagenlecleucel
          3. By Brexucabtagene Autoleucel
          4. By Other Drug Types
        2. Rest of Asia Pacific CAR T-Cell Therapy Market, By Indication
          1. By Lymphoma
          2. By Acute Lymphocytic Leukemia
          3. By Other Indications
        3. Rest of Asia Pacific CAR T-Cell Therapy Market, By End User
          1. By Hospitals
          2. By Cancer Treatment Centers
  7. Latin America CAR T-Cell Therapy Market - Segment Analysis
    1. Overview
    2. Latin America CAR T-Cell Therapy Market, 2016 - 2028 (USD Million)
    3. Latin America CAR T-Cell Therapy Market, by Drug Type
      1. By Axicabtagene Ciloleucel
      2. By Tisagenlecleucel
      3. By Brexucabtagene Autoleucel
      4. By Other Drug Types
    4. Latin America CAR T-Cell Therapy Market, by Indication
      1. By Lymphoma
      2. By Acute Lymphocytic Leukemia
      3. By Other Indications
    5. Latin America CAR T-Cell Therapy Market, by End User
      1. By Hospitals
      2. By Cancer Treatment Centers
    6. Latin America CAR T-Cell Therapy Market, by Country
      1. Brazil
        1. Brazil CAR T-Cell Therapy Market, By Drug Type
          1. By Axicabtagene Ciloleucel
          2. By Tisagenlecleucel
          3. By Brexucabtagene Autoleucel
          4. By Other Drug Types
        2. Brazil CAR T-Cell Therapy Market, By Indication
          1. By Lymphoma
          2. By Acute Lymphocytic Leukemia
          3. By Other Indications
        3. Brazil CAR T-Cell Therapy Market, By End User
          1. By Hospitals
          2. By Cancer Treatment Centers
      2. Argentina
        1. Argentina CAR T-Cell Therapy Market, By Drug Type
          1. By Axicabtagene Ciloleucel
          2. By Tisagenlecleucel
          3. By Brexucabtagene Autoleucel
          4. By Other Drug Types
        2. Argentina CAR T-Cell Therapy Market, By Indication
          1. By Lymphoma
          2. By Acute Lymphocytic Leukemia
          3. By Other Indications
        3. Argentina CAR T-Cell Therapy Market, By End User
          1. By Hospitals
          2. By Cancer Treatment Centers
      3. Rest of Latin America
        1. Rest of Latin America CAR T-Cell Therapy Market, By Drug Type
          1. By Axicabtagene Ciloleucel
          2. By Tisagenlecleucel
          3. By Brexucabtagene Autoleucel
          4. By Other Drug Types
        2. Rest of Latin America CAR T-Cell Therapy Market, By Indication
          1. By Lymphoma
          2. By Acute Lymphocytic Leukemia
          3. By Other Indications
        3. Rest of Latin America CAR T-Cell Therapy Market, By End User
          1. By Hospitals
          2. By Cancer Treatment Centers
  8. Middle East & Africa CAR T-Cell Therapy Market - Segment Analysis
    1. Overview
    2. Middle East & Africa CAR T-Cell Therapy Market, 2016 - 2028 (USD Million)
    3. Middle East & Africa CAR T-Cell Therapy Market, by Drug Type
      1. By Axicabtagene Ciloleucel
      2. By Tisagenlecleucel
      3. By Brexucabtagene Autoleucel
      4. By Other Drug Types
    4. Middle East & Africa CAR T-Cell Therapy Market, by Indication
      1. By Lymphoma
      2. By Acute Lymphocytic Leukemia
      3. By Other Indications
    5. Middle East & Africa CAR T-Cell Therapy Market, by End User
      1. By Hospitals
      2. By Cancer Treatment Centers
    6. Middle East & Africa CAR T-Cell Therapy Market, by Country
      1. GCC Countries
        1. GCC Countries CAR T-Cell Therapy Market, By Drug Type
          1. By Axicabtagene Ciloleucel
          2. By Tisagenlecleucel
          3. By Brexucabtagene Autoleucel
          4. By Other Drug Types
        2. GCC Countries CAR T-Cell Therapy Market, By Indication
          1. By Lymphoma
          2. By Acute Lymphocytic Leukemia
          3. By Other Indications
        3. GCC Countries CAR T-Cell Therapy Market, By End User
          1. By Hospitals
          2. By Cancer Treatment Centers
      2. South Africa
        1. South Africa CAR T-Cell Therapy Market, By Drug Type
          1. By Axicabtagene Ciloleucel
          2. By Tisagenlecleucel
          3. By Brexucabtagene Autoleucel
          4. By Other Drug Types
        2. South Africa CAR T-Cell Therapy Market, By Indication
          1. By Lymphoma
          2. By Acute Lymphocytic Leukemia
          3. By Other Indications
        3. South Africa CAR T-Cell Therapy Market, By End User
          1. By Hospitals
          2. By Cancer Treatment Centers
      3. Rest of Middle East & Africa
        1. Rest of Middle East & Africa CAR T-Cell Therapy Market, By Drug Type
          1. By Axicabtagene Ciloleucel
          2. By Tisagenlecleucel
          3. By Brexucabtagene Autoleucel
          4. By Other Drug Types
        2. Rest of Middle East & Africa CAR T-Cell Therapy Market, By Indication
          1. By Lymphoma
          2. By Acute Lymphocytic Leukemia
          3. By Other Indications
        3. Rest of Middle East & Africa CAR T-Cell Therapy Market, By End User
          1. By Hospitals
          2. By Cancer Treatment Centers
  9. Key Market Dynamics
    1. Introduction
    2. Market Drivers
    3. Market Restraints
    4. Market Opportunities
    5. Porter's Five Forces Analysis
    6. PEST Analysis
    7. Regulatory Landscape
    8. Technology Landscape
    9. Regional Market Trends
  10. COVID 19 Impact Analysis
    1. Key strategies undertaken by companies to tackle COVID-19
    2. Short term dynamics
    3. Long term dynamics
  11. Marketing Stratagy Analysis
    1. Marketing Channel
    2. Direct Marketing
    3. Indirect Marketing
    4. Marketing Channel Development Trends
  12. Competative Landscape
    1. Competition Matrix - 2021
    2. Company Market Share Analysis - 2021
    3. Key Company Activities, 2018 - 2021
    4. Strategic Developments - Heat Map Analysis
    5. Company Offering Evaluation
    6. Company Regional Presence Evaluation
  13. Company Profiles
    1. Celgene Corporation (U.S.)
    2. Cartesian Therapeutics Inc. (U.S.)
    3. Miltenyi Biotech (Germany)
    4. Autolus Therapeutics (UK)
    5. Caribou Biosciences Inc. (U.S.)
    6. Gilead Sciences Inc. (U.S.)
    7. Merck & Co. Inc. (U.S.)
    8. Intellia Therapeutics (U.S.)
    9. Juno Therapeutics Inc. (U.S.)
    10. Bristol-Myers Squibb (U.S.)
    11. Novartis AG (Switzerland)
    12. Bluebird Bio Inc. (U.S.)
    13. Sorrento Therapeutics Inc. (U.S.)
    14. Pfizer Inc. (U.S.)
    15. Cellectis (France)
    16. Celyad Oncology (Belgium)
  14. Key Primary Respondents - VERBATIM
  15. Discussion Guide
  16. Customization Offered
  17. Annexure
  18. List of Figures
  19. List of Tables
  20. List of Abbreviations
FAQ
Frequently Asked Question
  • The global CAR T-Cell Therapy valued at USD 2 Billion in 2022 and is expected to reach USD 5.9 Billion in 2030 growing at a CAGR of 14.6%.

  • The prominent players in the market are Celgene Corporation (U.S.), Cartesian Therapeutics Inc. (U.S.), Miltenyi Biotech (Germany), Autolus Therapeutics (UK), Caribou Biosciences Inc. (U.S.), Gilead Sciences Inc. (U.S.), Merck & Co. Inc. (U.S.), Intellia Therapeutics (U.S.), Juno Therapeutics Inc. (U.S.), Bristol-Myers Squibb (U.S.), Novartis AG (Switzerland), Bluebird Bio Inc. (U.S.), Sorrento Therapeutics Inc. (U.S.), Pfizer Inc. (U.S.), Cellectis (France), Celyad Oncology (Belgium).

  • The market is project to grow at a CAGR of 14.6% between 2023 and 2030.

  • The driving factors of the CAR T-Cell Therapy include

    • Surge in prevalence of cancer

  • North America was the leading regional segment of the CAR T-Cell Therapy in 2022.